Voloridge Investment Management
YMAB

Voloridge Investment Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Voloridge Investment Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12,988
Closed -$393K – 1819
2021
Q1 		$393K Buy
+12,988
New +$532K ﹤0.01% 1221
2020
Q3 		– Sell
-15,763
Closed -$681K – 1541
2020
Q2 		$681K Buy
+15,763
New +$596K 0.01% 957
2020
Q1 		– Sell
-27,344
Closed -$855K – 1447
2019
Q4 		$855K Buy
+27,344
New +$809K 0.02% 692

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Voloridge Investment Management's YMAB Position: Q2 2021 in Review

Voloridge Investment Management sold out of Y-mAbs Therapeutics (YMAB) in Q2 2021, closing a stake of 12,988 shares — an estimated $393K sold.

Voloridge Investment Management first reported a position in YMAB in Q4 2019 and held it in 3 quarters. The position peaked at $855K in Q4 2019. 100 funds tracked by Wall St. Rank hold YMAB as of Q2 2021.

  • Voloridge Investment Management reported no remaining Y-mAbs Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Voloridge Investment Management sold 12,988 Y-mAbs Therapeutics shares in Q2 2021, an estimated $393K.
  • Voloridge Investment Management first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 3 quarters.
  • Voloridge Investment Management's Y-mAbs Therapeutics position peaked at $855K in Q4 2019.
  • 100 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2021.

Based on Voloridge Investment Management's 13F filing for Q2 2021, filed 16 Aug 2021.